Dyadic International Inc - Asset Resilience Ratio
Dyadic International Inc (DYAI) has an Asset Resilience Ratio of 26.55% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Dyadic International Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Dyadic International Inc's Asset Resilience Ratio has changed over time. See Dyadic International Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Dyadic International Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DYAI stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.10 Million | 26.55% |
| Total Liquid Assets | $3.10 Million | 26.55% |
Asset Resilience Insights
- Very High Liquidity: Dyadic International Inc maintains exceptional liquid asset reserves at 26.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Dyadic International Inc Industry Peers by Asset Resilience Ratio
Compare Dyadic International Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Dyadic International Inc (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Dyadic International Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 27.76% | $2.76 Million | $9.93 Million | +18.66pp |
| 2023-12-31 | 9.10% | $748.29K | $8.22 Million | -40.83pp |
| 2022-12-31 | 49.93% | $6.85 Million | $13.71 Million | +28.75pp |
| 2021-12-31 | 21.18% | $4.51 Million | $21.30 Million | -6.94pp |
| 2020-12-31 | 28.12% | $8.46 Million | $30.07 Million | -50.37pp |
| 2019-12-31 | 78.50% | $29.40 Million | $37.45 Million | -11.15pp |
| 2018-12-31 | 89.64% | $38.82 Million | $43.30 Million | +7.08pp |
| 2017-12-31 | 82.57% | $41.90 Million | $50.74 Million | +10.93pp |
| 2016-12-31 | 71.64% | $42.05 Million | $58.70 Million | +70.21pp |
| 2014-12-31 | 1.43% | $122.00K | $8.54 Million | +0.09pp |
| 2013-12-31 | 1.34% | $200.00K | $14.94 Million | -0.15pp |
| 2012-12-31 | 1.49% | $192.00K | $12.88 Million | -0.59pp |
| 2011-12-31 | 2.08% | $214.00K | $10.30 Million | -0.34pp |
| 2010-12-31 | 2.41% | $247.00K | $10.23 Million | +0.21pp |
| 2009-12-31 | 2.20% | $316.00K | $14.36 Million | -1.10pp |
| 2008-12-31 | 3.30% | $344.00K | $10.43 Million | +1.96pp |
| 2007-12-31 | 1.34% | $349.00K | $26.09 Million | +1.19pp |
| 2005-12-31 | 0.15% | $35.00K | $23.75 Million | -- |
About Dyadic International Inc
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and la… Read more